|国家预印本平台
首页|不同类型骨科疾患患者D-二聚体与纤维蛋白原检测

不同类型骨科疾患患者D-二聚体与纤维蛋白原检测

中文摘要英文摘要

目的 分析不同类型骨科疾患患者血浆中D-二聚体与纤维蛋白原的水平,探讨不同类型骨科疾患患者并发血栓性疾病倾向性。方法 对患有不同类型骨科疾患的患者血浆D-二聚体、纤维蛋白原(FIB)及其他凝血指标凝血酶原时间、部分活化凝血活酶时间、凝血酶时间和白细胞、血小板的检测结果进行统计分析。结果 所有病例组D-二聚体升高程度和异常率最高,其次为FIB,其值在各组中从高到低依次为股骨骨折组、胸椎腰椎骨折组、其他骨折组、椎间盘突出组、关节病组,各病例组与健康对照组比较差异有统计学意义(P<0.05);D-二聚体异常率股骨骨折组为100%,胸腰椎骨折组94%,其他骨折组88.23%,关节病组64.56%,椎间盘突出组62.63%。结论 除了骨折和手术患者D-二聚体升高明显之外,其他各类骨科疾患患者血浆D-二聚体水平和FIB也都普遍升高,提示不同骨科疾患患者都有并发血栓性疾病的倾向,密切观察D-二聚体和FIB水平,警惕深静脉血栓的发生。

Objective To analyze the levels of D-dimer and fibrinogen in plasma of patients with different types of orthopedicdiseases, and to explore the tendency of patients with different types of orthopedic disorders complicated with thromboticdiseases. Methods The measured results of D-dimer, FIB, PT, APTT, TT, WBC and PLT were compared in patients withdifferent types of orthopedic diseases. Results The measured results and rate of abnormality of D-dimer in all groups were thehighest.The second was FIB.From higher to lower in turn for group of femoral fracture, thoracic vertebr and lumbar vertebralfracture, other fracture, cervical vertebra and lumbar disc herniation, the joint disease.Compared with healthy control group,the measured results and rate of abnormality of D-dimer and FIB were significant different. The rate of abnormality of D-dimerin the group of femoral fracture was 100%, thoracic vertebr and lumbar vertebral fracture 94%, other fracture 88.23%, the jointdisease 64.56%, cervical vertebra and lumbar disc herniation 62.63%. Conclusion In addition to fracture and surgery patientswith significant increase in D-dimer, the other types of orthopedic disorders in patients with plasma D-dimer levels and FIBare generally increased.It means that patients with different orthopedic disorders have thrombotic disease tendencies, closeobservation of D-dimer and FIB levels, alert to the occurrence of deep vein thrombosis.

余佩芝;赵丽香

10.12074/201712.00428V1

临床医学外科学基础医学

骨科疾患-二聚体纤维蛋白原深静脉血栓

余佩芝;赵丽香.不同类型骨科疾患患者D-二聚体与纤维蛋白原检测[EB/OL].(2017-12-07)[2025-08-18].https://chinaxiv.org/abs/201712.00428.点此复制

评论